Safe Harbor Statements Forward-Looking Statements Certain statements contained in this corporate presentation (this "Presentation"), along with certain statements that may be made by management of Scilex Holding Company

Innovative Leader in Non-Opioid Pain

Therapeutics (June 2023) Confidential Exhibit 99.1

Safe Harbor Statements Forward-Looking

Statements Certain statements contained in this corporate presentation (this "Presentation"), along with certain statements that may be made by management of Scilex Holding Company (together with its subsidiaries, "Scilex")

orally in presenting this material, are or may be considered "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly

to historic or current facts. Forward-looking statements are typically identified by words such as "estimate," "expect,""intend," "believe," "plan," "anticipate,"

"potential," "projected" and other words and terms of similar meaning (including the negative of any of the foregoing) in connection with any discussion of future operating or financial performance or condition, but the

absence of these words does not mean that a statement is not forward-looking. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are

forward-looking statements. Scilex cautions that these statements are based upon information available as of the date of this Presentation and the current beliefs and expectations of Scilex's management and are subject to significant risks,

uncertainties and assumptions. Statements regarding future actions, future performance and/or future results including, without limitation, those relating to the timing for completion, and results of, scheduled or additional clinical trials and the

FDA's or other regulatory review and/or approval and commercial launch and sales results (if any) of Scilex's formulations and products and regulatory filings related to the same, financial projections and targets, business strategy and

plans and objectives for future operations may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. In light of these risks, uncertainties and assumptions, the

forward-looking events and circumstances discussed in this Presentation are inherently uncertain and may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

Accordingly, you should not rely upon forward-looking statements as predictions of future events. Scilex undertakes no obligation to update publicly or revise any forward-looking statements for any reason after the date of this Presentation or to

conform these statements to actual results or to changes in Scilex's expectations, weather as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under

applicable securities laws. For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to Scilex's filings with the Securities and Exchange

Commission ("SEC"), including the risk factors obtained in the Company's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Industry and Market Data Certain data in this

Presentation was obtained from various external sources, and neither Scilex nor its affiliates, advisers or representatives has verified such data with independent sources. Accordingly, neither Scilex nor any of its affiliates, advisers or

representatives makes any representations as to the accuracy or completeness of that data or undertakes any obligation to update such data after the date of this Presentation. Such data involves risks and uncertainties and is subject to change based

on various factors. Trademarks The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Scilex. Important

Information and Where to Find It This Presentation does not constitute an offer to sell or exchange, or the solicitation of an offer to buy or exchange, any securities, nor shall there be any sale of securities in any jurisdiction in which such

offer, sale or exchange would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Investors and securityholders will be able to obtain free copies of the reports that the Company has filed or may

subsequently file with the SEC through the website maintained by the SEC at www.sec.gov.

Executive Summary Company Background

Scilex Holding Company ("Scilex") is an innovative revenue-generating pharmaceutical firm focused on developing and commercializing non-opioid acute and chronic pain management products Scilex targets indications with unmet needs and

large market opportunities in acute and chronic pain, including shingles, migraine, gout, sciatica and fibromyalgia Lead commercial product, ZTlido 1.8%, is a prescription lidocaine topical product for the relief of neuropathic pain associated with

postherpetic neuralgia PHN (shingles pain). FDA-approved product Elyxyb (acute migraine) launched in April 2023 Additional planned 2023 launch for FDA-approved product Gloperba (gout) Scilex has multiple products in its pipeline, including a Phase 3

candidate, a Phase 2 candidate and a Phase 1 candidate that is expected to enter Phase 2 in 2023: SP-102 (SEMDEXA ) - a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat sciatica

SP-103 (5.4%) - a Phase 2, next-generation triple strength formulation of ZTlido for the treatment of low back pain SP-104 - a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia Feb.

2018: Scilex receives final FDA approval for ZTlido (for the treatment of postherpetic neuralgia) Mar. 2019: Scilex Holding Company formed with the acquisition of Semnur Pharmaceuticals Oct. 2018: Scilex launches ZTlido commercially in

the U.S. Nov. 2022: Scilex goes public via merger with Vickers Vantage Corp. I with post-money equity value of ~$1.64B Dec. 2022: Sorrento declares stock distribution of ~76mm shares; eligible Sorrento stockholders to receive pro-rate share of

Scilex stock distributed in Jan 2023 Feb. 2023: Acquires and announces commercial launch of Elyxyb in United States (launched in April 2023) Mar. 2023: Announces FY2022 earnings, including revenues of $38mm (21% y-o-y growth) Company Overview

Corporate Timeline Jun. 2022: Acquires Gloperba in United States (expected to launch in 2023)

Investment Highlights Executive

Summary Established Reimbursement Access Strong Proprietary Platform with High Barriers to Entry Worldwide Commercial Rights to Most Product Candidates 3 FDA-approved Non-Opioid Acute and Chronic Pain Management Products 2 3 4 1 Blockbuster Pipeline

With Limited Capital Required for Commercialization 5

Platform Program IND Phase 1

ZTlido 1.8% (Postherpetic Neuralgia-PHN) GLOPERBA (colchicine USP) oral solution (Treatment of Gout) SP-102 (SEMDEXA) (Lumbar Radicular / Sciatica Pain) SP-103 Lidocaine Topical System 5.4% (3X) (Acute Back Pain) SP-104, Delayed Burst

Low Dose Naltrexone (Fibromyalgia) Phase 2 Phase 3 Pivotal NDA Approved Upcoming Milestones Fast Track and Pre NDA Innovative Non-Opioid Pain Therapeutics Executive Summary KEY PROGRAMS PRECLINICAL PHASE 1 PHASE 2 PHASE 3 / PIVOTAL APPROVED IP

MILESTONES / KEY COMMENTARY ZTlido (1.8% lidocaine topical system equivalent to 5% lidocaine) 2031 Launched in the U.S. in October 2018 GLOPERBA (colchicine USP) oral solution (For the prevention of painful gout flares in adults) 2036 2H

2022: In-licensed U.S. rights Q4-2023: U.S. launch ELYXYB (celecoxib) oral solution (Acute Treatment of Migraine) 2036 1Q 2023: In-licensed U.S. / Canadian rights 2Q 2023: U.S. launch SP-102 (SEMDEXA ) (Lumbar Radicular / Sciatica Pain)

2036 1H 2022: Phase III achieved endpoints 1H 2023: FDA discussion on Pre-NDA SP-103 Lidocaine Topical System 5.4% (3X) (Acute Back Pain) 2031 2Q 2022: Initiated Phase II trial SP-104, Delayed Burst Low Dose Naltrexone (Fibromyalgia) 2041 1H 2022:

Completed Phase I trial(s) 2023: Initiate Phase II trials Approved for the treatment of Postherpetic Neuralgia-PHN related pain Fast Track / Pre-NDA Fast Track Approved for acute treatment of migraine Approved for the prevention of painful gout

flares in adults Prepare Phase II Trial

ZTlido (1.8% lidocaine topical system

equivalent to 5% lidocaine for the treatment of Postherpetic Neuralgia-PHN related pain)

ZTlido Sales Performance 2022 - YTD

2023 YTD May 2023 Gross sales were in the range of $49.2 million to $54.3 million, compared to $32.0 million for year-to-date May 2022, representing growth in the range of 54% to 70% Net sales were in the range of $16.0 million to $19.0 million,

compared to $11.4 million for year-to-date May 2022, representing growth in the range of 40% to 67%. Q1-2023 Gross sales for the first quarter of 2023 were $27.5 million, compared to $18.4 million in the first quarter of 2022, representing growth of

49%. Net sales for the first quarter of 2023 were $10.6 million, compared to net sales of $6.8 million in the first quarter of 2022, representing growth of 56%. Historically, sales for ZTlido are low during the first quarter of the year due to

deductibles with managed healthcare plans. Full Year 2022 Net sales for full year 2022 were $38.0 million, compared to net sales of $31.3 million in 2021, representing a growth of 21%.

ZTlido Commercialization

ZTlido 1.8% (FDA approved for

relief of PHN pain) Only ZTlido delivers a 12-hour adhesion in a non-opioid therapy Superior adhesion versus other lidocaine patches in various head-to-head studies Only lidocaine patch proven in moderate exercise Savings & support system makes

it easy to receive inexpensive monthly prescription Lidocaine Patch Market Overview +4.6mm prescriptions in 2022 +169mm prescription lidocaine patches sold in the U.S. in 20221 Benefits versus Other Lidocaine Patches Superior adhesion compared to

other lidocaine patches head-to-head studies Only lidocaine patch proven in moderate exercise How does it compare to Lidoderm (5%) (1) Symphony Healthcare Properties ZTlido (1.8%) Lidoderm (5%) Bioavailability ~45% ~3 2% Weight 2 grams 14

grams Thickness 0.8 millimeters 1.6 millimeters Lidocaine Content 36 milligrams 700 milligrams Adhesion Non-aqueous Water-based 1 2 3

ZTlido Market Access Update ZTlido

Covered Lives Overview 62 Key Players - Preference State of California (MediCal) Lidocaine Preferred ZTlido Preferred ZTlido Preferred ZTlido Preferred

The ZTlido Solution to the Unmet

Need with Gabapentinoids

The ZTlido New Campaign as the

ideal add-on to Gabapentinoids Confidential, not for distribution Designed to allow the brand to achieve its true potential by repositioning from Adhesion to Efficacy) ZTlido is uniquely capable of optimizing gabapentinoids - doubling efficacy

without the baggage/side effects of other analgesic options (opioids, TCAs, SNRIs, NSAIDs, Acetaminophen). This combination efficacy data is "new' as HCPs are unaware of it - we can own the data as we believe we are the only

lidocaine patch being actively promoted. Aligns with managed care thinking (step edit ZTlido through gabapentinoids) Takes us into a 10X bigger market (gabapentinoids) than the lidocaine patch market

Enhanced Patient Quality of Life

Enhanced Patient Quality of Life:

Elyxyb (celecoxib) oral solution

(Acute Treatment of Migraine)

Elyxyb Launched in USA April

Approximately 39M People with

Migraine in the US Some patients may receive both acute as well as preventive treatment Source: Prevalence by Migraine Research Foundation, 2021; Epidemiology data by DRG

ELYXYB has an opportunity to

address unmet need for fast-acting acute migraine therapies as patients cycle through standard therapies Sources: 1. Migraine Research Foundation, 2021; 2. Evaluate Pharma data February 16, 2023 ; 3. Lipton RB et al. Headache. 2017; 4. IQVIA NPA

Monthly YTD 2022; 5. Symphony Health Patient Claims; 6. Parduzt, NSAIDs in the Acute Treatment of Migraine: A review of Clinical Experiment and Data, 2010; Market Overview and Value Proposition Large and Growing U.S. Market High Unmet Need in Acute

Setting First and Only COX-2 Inhibitor of Its Kind 39 million people suffer from migraines in the US, of which 9 million (23%) are on acute Rx therapies1 US oral migraine market is expected to be $1.8B in 20222 >70% of patients report inadequate

treatment response with acute migraine3 (primarily Triptans and NSAIDs) OTC NSAIDs used first-line in acute settings but often associated with GI adverse events and/or slower onset of action Acute migraine market dominated by Triptans (>70% of

prescriptions)4 CGRPs showing discontinuation at a high rate (~50% therapy abandonment 90-day post start)5 First and only COX-2 inhibitor formulated as a fast-onset oral solution for the acute treatment of migraine Specifically developed to work

fast for migraine: Unique delivery system improves bioavailability / absorption Fast onset of action: Median TMax of 1 hour Efficacious: Proven in 2 large Phase 3 studies of 815 patients Safety: No serious adverse events, no drowsiness and favorable

GI side effect profile vs traditional NSAIDs Convenience: Ready-to-use oral solution - no prep, no steps, just open and drink

The US Migraine Market Is Projected

To Grow By 195% Between 2021 to 2026 Source: Evaluate; Above data includes both acute and preventative therapies; Data refreshed in January 2022

Gloperba (colchicine USP) oral

solution (For the prevention of painful gout flares in adults)

Gloperba Launch in USA Planned in

Gout Market Size Overview 5.0 9.0

1.6 2.4 Sources: Chen-Xu M, et al. Arthritis Rheum. 2019;72(6):991-999; Symphony Healthcare Confidential, not for distribution

Gout Unmet Needs Gloperba HCP

Market Research Source: Rheumatologists and PCPs interviewed by Percipient, November - February 2023 n=39 "A drug that doesn't have any GI adverse events would be good. It should have no side effects. It can't cause toxicity

either, considering [tablet] colchicine is already effective." - Rheumatologist Physicians are generally satisfied with the currently available prophylactic gout treatments, particularly colchicine. However, physicians acknowledged that

colchicine's ability to cause adverse GI events along with the caution that must be taken when prescribing it to patients with comorbidities warrant new drugs with significantly improved safety profiles. "Patients don't always

adhere to colchicine. We need drugs that patients will take without the GI side effects. Otherwise, it's a very effective drug." - Rheumatologist "There is an unmet need for drugs that can be used in patients who can't

tolerate the GI side effects." - PCP Confidential, not for distribution

SP-102 (SEMDEXA) Treatment of

Chronic Low Back Pain/ Sciatica

CURRENT PROBLEM Prescription opioid

abuse is at epidemic proportions in the U.S1 Additionally, the CDC states that opioids do not provide clinically meaningful pain relief in patients with low back and chronic pain2 MULTI-MODAL PAIN MANAGEMENT Multiple medical organizations recommend

multi-modal analgesia for chronic pain management, including the American Society of Anesthesiologists (ASA), American Society of Regional Anesthesia (ASRA) & the American Academy of Orthopedic Surgeons. POTENTIAL FOR SP-102 SEMDEXA (SP-102)

clinical program is intended to demonstrate its utility as a key adjunct treatment for low back pain/lumbar radiculopathy and potential as a new pain management standard Center for Disease Control and Prevention. Increases in Drug and Opioid

Overdose Deaths 2000-20014. MMWR 2015; 64; 1-5. Efficacy, Tolerability and Dose Effects of Opioid Analgesics for Low Back Pain. JAMA Internal Medicine. 2016 Jul 1; 176 Practice Guidelines for Chronic Pain Management. Anesthesiology. 2010; 112: No 4